Mantle Cell Lymphoma
From the Journals
New inhibitor shows promise in previously failed B-cell malignancies
Pirtobrutinib (formerly known as LOXO-305) is an oral-dose, highly selective, reversible inhibitor.
Management of refractory mantle cell lymphoma
Conference Coverage
Survey quantifies COVID-19’s impact on oncology
Oncologists detail how COVID-19 has impacted care, caregivers, continuing medical education, and clinical trials.
From the Journals
Hepatitis screening now for all patients with cancer on therapy
All patients with cancer who are candidates for systemic therapy should be screened for hepatitis B, says the American Society of Clinical...
News
FDA okays new CAR T therapy, first for mantle cell lymphoma
Roundtables
Mantle Cell Lymphoma 2020 Roundtable Discussion
From the Journals
COVID-19: Experts hasten to head off mental health crisis
Across the two surveys, respondents’ primary concern was anxiety, which was cited in 750 responses.
Video
Experts break down latest CAR T-cell advances in lymphoma
ORLANDO – An expert panel of physicians discusses the latest research on CAR T-cell therapy in lymphoma, presented at the 2019 annual meeting of...
Conference Coverage
LOXO-305: Next-gen BTK inhibitor safe and effective in B-cell malignancies
ORLANDO – The antitumor activity of the novel drug was significant among patients with chronic lymphocytic leukemia and mantle cell lymphoma.
Conference Coverage
Some MCL patients can safely stop venetoclax-ibrutinib, study suggests
ORLANDO - The study raises the possibility of limited-duration, targeted-agent therapy in relapsed/refractory mantle cell lymphoma.
Conference Coverage
KTE-X19 produces highest response rate in MCL subgroup
ORLANDO – The CAR T-cell therapy produced the highest reported response rate in mantle cell lymphoma patients who have failed treatment with a...